ALBUMINURIA IS A TARGET FOR RENOPROTECTIVE THERAPY INDEPENDENT FROM BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY: POST-HOC ANALYSIS FROM THE REDUCTION OF ENDPOINTS IN NIDDM WITH THE ANGIOTENSIN II ANTAGONIST LOSARTAN (RENAAL) TRIAL

EIJKELKAMP, W.B., ZHANG, Z., & REMUZZI, G.. (2007). ALBUMINURIA IS A TARGET FOR RENOPROTECTIVE THERAPY INDEPENDENT FROM BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY: POST-HOC ANALYSIS FROM THE REDUCTION OF ENDPOINTS IN NIDDM WITH THE ANGIOTENSIN II ANTAGONIST LOSARTAN (RENAAL) TRIAL. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (JASN), 18(-), 1540-1546. SID. https://sid.ir/paper/686582/en

EIJKELKAMP W.B., ZHANG Z., REMUZZI G.. ALBUMINURIA IS A TARGET FOR RENOPROTECTIVE THERAPY INDEPENDENT FROM BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY: POST-HOC ANALYSIS FROM THE REDUCTION OF ENDPOINTS IN NIDDM WITH THE ANGIOTENSIN II ANTAGONIST LOSARTAN (RENAAL) TRIAL. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (JASN)[Internet]. 2007;18(-):1540-1546. Available from: https://sid.ir/paper/686582/en

W.B. EIJKELKAMP, Z. ZHANG, and G. REMUZZI, “ALBUMINURIA IS A TARGET FOR RENOPROTECTIVE THERAPY INDEPENDENT FROM BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY: POST-HOC ANALYSIS FROM THE REDUCTION OF ENDPOINTS IN NIDDM WITH THE ANGIOTENSIN II ANTAGONIST LOSARTAN (RENAAL) TRIAL,” JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (JASN), vol. 18, no. -, pp. 1540–1546, 2007, [Online]. Available: https://sid.ir/paper/686582/en